Genetic Risk Factors of the Autoimmune Diabetes Mellitus, theirSignificance and Function
Authors:
P. Novota 2; P. Čejková 1; M. Černá 1; M. Anděl 3
Authors‘ workplace:
CBO – Oddělení buněčné a molekulární biologie 3. LF UK, Praha 2Oddělení imunogenetiky IKEM, Praha 3II. interní klinika 3. LF UK a FNKV, Praha
1
Published in:
Čas. Lék. čes. 2004; : 159-163
Category:
Overview
Autoimmune diabetes mellitus is characterized by selective destruction of β pancreatic cells and by cellularinfiltration with T-(p articularly Th1) and B-lymphocytes. The marker of autoimmunity is the presence of autoantibodies(ICA, IAA, GADab, IA2ab). Etiology of the autoimmune process is still unknown. It is suggested that thepathogenesis is activated by genetic and environmental factors. Individual predisposition can influence also the onsetand progression of the disease. The most important genetic risk factors of autoimmune diabetes mellitus are the HLAclass II alleles (DQB1*0302, 0201; DRB1*0301, 0401; DQA1*0301, 0501) and the risk alleles of INS-VNTR ofthe promoter region. Recent studies have shown various genetic risk factors for the autoimmune diabetes mellitus.Individual predispositions belong to the genetic polymorphisms in cytokine genes (IL-10, IL-12, IL-18) and themicrosatelite polymorphism of MHC class I chain-related gene A (MIC-A).
Key words:
diabetes mellitus, genetic risk factor, HLA, insulin, interleukin, MIC-A.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Molecular Diagnostics of Malignant B Cell Lymphomas: Detection ofClonality and a Brief Review with our Own Results
- Intelligence Loss in Phatic Disorders
- Budd-Chiari Syndrome in Patient with Primary ThrombocythaemiaTreated with Interferon Alpha Medically Managed by Transjugular Porto-systemic Shunt
- Results of Clinical Study of Patients Suffering from Hodgkin’s Lymphomaafter 25 Years